Navigation Links
Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
Date:11/14/2007

PT. RICHMOND, Calif., Nov. 14 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, will present at the 19th Annual Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on Tuesday, November 27, 2007 at 10:30 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill, Investors / Media

Director of Communications Stephanie Carrington / Jason Rando

(510) 215-3575 (646) 536-7017 / 7025

mgill@transcept.com scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... , ... The Celebrity Dresses is currently running a promotion through July 30th. ... have the opportunity to get 10% discount on orders that are over $100. , ... to use coupon codes or remember redemption codes. , There is a low ...
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Texas. The opening is now the 19th sweetFrog store located in the Lone Star ... list of fastest growing companies in 2014. , The store, which opened July 1 ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the parking structure retrofit project at the University of Minnesota, they knew it ... that it would also be an award-winning choice: the total energy savings after ...
(Date:7/2/2015)... ... 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry was fully ... to write his first poem, and three years later he was publishing an entire book ... sharing with the world. "I have always believed that the best way to lift yourself ...
(Date:7/2/2015)... ... 02, 2015 , ... Get ready to hit the gym, ... the socks were first introduced, they have rapidly been gaining attention among active ... new, fun shades including: blue, lime, pink and red. , Utilizing innovative ...
Breaking Medicine News(10 mins):Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
... News) -- Intensive control of blood sugar levels reduces ... diabetics, new research indicates. However, the evidence did ... actually developing severe kidney disease. The two signs ... conditions known as microalbuminuria and macroalbuminuria. These are characterized ...
... (May 29, 2012) Researchers from South Korea, Sweden, ... to restore neuron function to parts of the brain ... pluripotent stem cells into animal models. Induced ... human somatic cells such as skin, and can be ...
... May 29, 2012 Older adults who don,t get ... exposure may be at increased risk of developing mobility ... Baptist Medical Center. , "This is one of the first ... the onset of new mobility limitations or disability in older ...
... genetic disorders have uncovered insights into those diseases ... divide. Focusing on the cohesin complex, a group ... pairs, scientists have discovered mutations that disrupt cohesin, ... cohesinopathies. "We are learning more about how ...
... May 29, 2012 -- The discovery of a mummified ... scientific team to conduct a genetic analysis on a liver ... C2 sequence common in Southeast Asia. Additional analysis ... model to study the evolution of chronic hepatitis B and ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
Cached Medicine News:Health News:Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study 2Health News:Researchers restore neuron function to brains damaged by Huntington's disease 2Health News:Older adults may need more vitamin D to prevent mobility difficulties 2Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
(Date:7/2/2015)... SHENZHEN, China , 2. Juli 2015 /PRNewswire/ ... Hochdurchsatz-Labor für DNA-Screening in Hongkong vom American ... BGI-Einrichtung in Hongkong ist das erste klinische ... ein CAP-Zertifkat erhält und somit ... Ergänzend zu den bestehenden US FDA - ...
(Date:7/2/2015)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... and tissue hypothermic storage and cryopreservation freeze ... chain management app for smart shippers ("BioLife" ... has included BioLife in its annual list of the ... state for 2015. Now in its ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3
... (MARKET WIRE) -- July 06, ... <a target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or ... the European Patent,Office has granted ... with claims related to,oral vaccination ...
... in The Lancet on TMC125, an Investigational ... /PRNewswire/ -- Data from two,ongoing Phase 3 ... adult patients with documented non-nucleoside reverse,transcriptase inhibitor ... undetectable viral load (defined as achieving,confirmed undetectable ...
Cached Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Paraffin Block Storage System...
The Tissue Cassette Storage Cabinet is made of strong, laminated fiberboard....
Plastic Block Filing Cabinet is a durable, six-drawer unit that holds up to 1500 slides....
Medicine Products: